Schizophrenia is an often disabling psychiatric disease that usually requires long-term treatment. The primary goals of medical treatment for schizophrenia are to reduce the frequency and severity of psychotic episodes, maintain the reduction in these symptoms over the long term, and improve patients’ functional capacity. Antipsychotics are the cornerstone of schizophrenia treatment, and the numerous atypical and typical antipsychotic drug classes available result in a complex treatment algorithm. Given the genericization of key oral therapies and the availability of newer oral, transdermal, and long-acting depot antipsychotics in the United States, such as Intra-Cellular Therapies’ Caplyta, AbbVie’s Vraylar, Noven’s Secuado, and Indivior’s Perseris, competition in the U.S. market continues to intensify. As such, understanding the nuanced schizophrenia treatment landscape is essential for assessing the remaining drug opportunities in this space.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Alkermes, Eli Lilly, Janssen, Indivior, Intra-Cellular Therapeutics, Lundbeck, Otsuka, Sumitomo Dainippon Pharma / Sunovion Pharmaceuticals
Key drugs: Abilify Maintena, Aristada, Invega Sustenna, Invega Trinza, Latuda, Rexulti, Risperdal Consta, Vraylar, Perseris, Caplyta, Secuado
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.